Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

GSK PLC closed 25.31% below its 52-week high of £18.24, which the company reached on May 16th.

Rating upgraded from 66 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.

GSK's Blenrep approved in the U.K. for multiple myeloma after strong phase 3 data showing improved survival in DREAMM-7 and ...

The London-based pharmaceutical company said Blenrep, or belantamab mafodotin, was approved for the treatment of adult patients with multiple myeloma in combination with bortezomib plus dexamethasone, ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports ...

If the tariff-loving Trump goes ahead with his plans, it will hit AstraZeneca - the most valuable company on the UK stock ...

Arrowhead Pharmaceuticals, Inc.’s ARWR share price has dipped by 12.32%, which has investors questioning if this is right ...

Coherus BioSciences, Inc.’s CHRS share price has dipped by 5.19%, which has investors questioning if this is right time to ...